• LAST PRICE
    3.0400
  • TODAY'S CHANGE (%)
    Trending Up0.0100 (0.3300%)
  • Bid / Lots
    2.7500/ 10
  • Ask / Lots
    3.0500/ 5
  • Open / Previous Close
    3.0300 / 3.0300
  • Day Range
    Low 2.9588
    High 3.1000
  • 52 Week Range
    Low 1.7900
    High 3.1000
  • Volume
    26,998
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 3.03
TimeVolumePMCB
09:32 ET9333.04
09:33 ET5003.03
09:37 ET18102.985
09:39 ET3003.04
09:42 ET41113.04
09:46 ET7003.031
10:24 ET1003.07
10:26 ET3003.07
10:56 ET9193.04
10:58 ET1563.0482
11:12 ET1003.04
11:23 ET3003.035
11:32 ET3003
11:50 ET6503.03
11:57 ET1003.03
02:14 ET1003.0054
02:23 ET1003.03
02:25 ET1003
02:30 ET31403.01
02:32 ET3003.01
02:38 ET12263.0101
02:43 ET1003.01
02:52 ET6563.0001
02:54 ET50003.02
03:08 ET1003.02
03:32 ET33753.018
03:48 ET1003.04
04:00 ET2003.04
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPMCB
PharmaCyte Biotech Inc
62.9M
-13.0x
---
United StatesGTBP
GT Biopharma Inc
59.6M
-1.7x
---
United StatesOCUP
Ocuphire Pharma Inc
64.7M
-2.5x
---
United StatesEQ
Equillium Inc
58.1M
-0.7x
---
United StatesEDTXF
Spectral Medical Inc
76.2M
-8.2x
---
United StatesORTX
Orchard Therapeutics PLC
56.5M
-0.3x
---
As of 2022-11-28

Company Information

PharmaCyte Biotech, Inc. is a biotechnology company. The Company is focused on developing and preparing to commercialize cellular therapies for cancer, diabetes and malignant ascites based upon its cellulose-based live cell encapsulation technology known as Cell-in-a-Box. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. The Cell-in-a-Box encapsulation technology enables genetically engineered live human cells to be used to produce various biologically active molecules. Its current generation of product candidates is referred to as CypCaps. It is developing therapies for pancreatic and other solid cancerous tumours by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated, genetically modified insulin-producing cells. The Company is also developing therapies for cancer that involve prodrugs based upon certain constituents of the cannabis plant.

Contact Information

Headquarters
23046 Avenida De La Carlota, Suite 600LAGUNA HILLS, CA, United States 92653
Phone
917-595-2850
Fax
917-595-2851

Executives

Interim Chairman of the Board, Interim President, Interim Chief Executive Officer
Joshua Silverman
Director
Robert Weinstein
Independent Director
Michael Abecassis
Independent Director
Daniel Allen
Independent Director
Daniel Farb

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$62.9M
Revenue (TTM)
$0.00
Shares Outstanding
20.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.13
EPS
$-0.23
Book Value
$4.34
P/E Ratio
-13.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.